Identification of STAT3/5 Advanced Preclinical Candidates

It is estimated that 1 in 2/3 people will be diagnosed with cancer in their lifetime. Cancer is a genetic disease characterized by the uncontrolled growth of cells. While treatments are available for many cancers, remission of the disease, side-effects of the medication, and the onset of resistance by the cancer to the drugs being used, contribute to the high fatality rates observed for several cancers. The blood cancers CML and AML are driven by the out-of-control activity of a protein in cancer cells called STAT5. Inhibition of STAT5 activity has been shown to cause cancer cells to die. The aim of this project is to optimize the properties of potential STAT5 inhibitor drugs develope at University of Toronto Mississauga, to allow them to be taken orally, and negate adverse side effects. This will be achieved in collaboration with the Leukemia and Lymphoma Society of Canada (LLSC), which aims to eradicate blood-borne cancers.

Faculty Supervisor:

Patrick Gunning

Student:

David Rosa

Partner:

CanPeptide

Discipline:

Chemistry

Sector:

Medical devices

University:

Program: